Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

Aubert I, Guigoni C, Håkansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E.

Ann Neurol. 2005 Jan;57(1):17-26.

PMID:
15514976
2.

Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E.

Neurobiol Dis. 2007 May;26(2):452-63. Epub 2007 Feb 9.

PMID:
17350277
3.

Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, Gurevich EV, Gross CE, Bezard E.

Eur J Neurosci. 2005 Jul;22(1):283-7.

PMID:
16029219
4.

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.

Biol Psychiatry. 2009 Sep 15;66(6):603-13. doi: 10.1016/j.biopsych.2009.04.025. Epub 2009 Jun 11.

PMID:
19520364
5.

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. Review.

PMID:
15885624
6.

L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.

Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R.

Biol Psychiatry. 2014 May 1;75(9):711-22. doi: 10.1016/j.biopsych.2013.05.006. Epub 2013 Jun 13.

PMID:
23769604
7.

Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.

Gross CE, Ravenscroft P, Dovero S, Jaber M, Bioulac B, Bezard E.

J Neurochem. 2003 Mar;84(6):1246-55.

8.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.

Neurobiol Dis. 2009 Aug;35(2):184-92. doi: 10.1016/j.nbd.2008.11.010. Epub 2008 Dec 9.

PMID:
19118628
9.

Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.

Neuroscience. 2005;132(2):409-20.

PMID:
15802193
10.

Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Farré D, Muñoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso-Reyes IG, Rico AJ, Lluís C, Mallol J, Navarro G, Canela EI, Cortés A, Labandeira-García JL, Casadó V, Lanciego JL, Franco R.

Mol Neurobiol. 2015 Dec;52(3):1408-1420. doi: 10.1007/s12035-014-8936-x. Epub 2014 Oct 26.

PMID:
25344317
11.

Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.

Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.

Synapse. 2008 Jul;62(7):524-33. doi: 10.1002/syn.20527. Erratum in: Synapse. 2008 Dec;62(12):958. Lucia, Frau [corrected to Frau, Lucia]; Annalisa, Pinna [corrected to Pinna, Annalisa]; Silvia, Pontis [corrected to Pontis, Silvia]; Nicola, Simola [corrected to Simola, Nicola]; Nicoletta, Schintu [corrected to Schintu, Nicoletta]; Micaela, Morelli [corrected to Morelli, Micaela].

PMID:
18435422
12.

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.

Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J.

Neuron. 2005 Feb 17;45(4):489-96.

13.

Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.

Lindgren HS, Ohlin KE, Cenci MA.

Neuropsychopharmacology. 2009 Nov;34(12):2477-88. doi: 10.1038/npp.2009.74. Epub 2009 Jul 15.

14.

Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.

Azkona G, Sagarduy A, Aristieta A, Vazquez N, Zubillaga V, Ruíz-Ortega JA, Pérez-Navarro E, Ugedo L, Sánchez-Pernaute R.

Neuropharmacology. 2014 Apr;79:726-37. doi: 10.1016/j.neuropharm.2013.11.024. Epub 2013 Dec 10.

PMID:
24333147
15.

Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.

Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E.

Sci Transl Med. 2010 Apr 21;2(28):28ra28. doi: 10.1126/scitranslmed.3000664.

16.

Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.

Jourdain VA, Morin N, Grégoire L, Morissette M, Di Paolo T.

J Neurosurg. 2015 Dec;123(6):1383-93. doi: 10.3171/2014.10.JNS141570. Epub 2015 May 1.

PMID:
25932606
17.

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Pavón N, Martín AB, Mendialdua A, Moratalla R.

Biol Psychiatry. 2006 Jan 1;59(1):64-74. Epub 2005 Sep 1.

PMID:
16139809
18.

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.

Oh JD, Bibbiani F, Chase TN.

Exp Neurol. 2002 Oct;177(2):557-64.

PMID:
12429201
19.

Supplemental Content

Support Center